Status:
NOT_YET_RECRUITING
Side Effects of Low Dose Rate Brachytherapy and Ultra-hypofractionated Radiotherapy in Low to Intermediate Risk Prostate Cancer
Lead Sponsor:
Royal Surrey County Hospital NHS Foundation Trust
Conditions:
Prostate Adenocarcinoma
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
The LDR BURST trial will compare the side effects of two radiotherapy treatments for men with localised prostate cancer. The first treatment is 4D low dose rate brachytherapy where small radioactive s...
Detailed Description
The hypothesis of the study is that treatment-related toxicity after Stereotactic Body Radiotherapy (SBRT) is not significantly different to that after Low Dose Rate (LDR) Brachytherapy. SBRT is an ec...
Eligibility Criteria
Inclusion
- Men aged ≥18 years at randomisation
- The research subject must have capacity to sign a written informed consent document for the trial
- WHO performance status 0 - 2
- Gleason score 3+3 or 3+4
- PSA ≤ 20 ng/ml (please note if the treating clinician determines androgen deprivation therapy (ADT) is required this is an exclusion criteria). A PSA must be available within 60 days of randomisation.
- Clinical and/or MRI stage T1c -T2c, N0-X, M0-X
- Histological confirmation of prostate adenocarcinoma within the last 18 months (unless on active surveillance). Patients who were on active surveillance should have an up-to-date MRI within 8 weeks of the decision to treat to confirm organ confined disease.
Exclusion
- Previous malignancy within the last 2 years (except basal cell carcinoma or squamous cell carcinoma of the skin), or if previous malignancy is expected to significantly compromise 10-year survival.
- Patients under investigation for synchronous primary at time of randomisation
- Prior pelvic radiotherapy.
- Prior treatment with ADT or current need for ADT based on risk features
- Prostate cancer in greater than 50% of template biopsy cores or a significant maximum core length containing prostate cancer for which the treating clinician deems the patient would benefit from ADT
- Any prior active treatment for prostate cancer (patients previously on active surveillance are eligible if they meet all other eligibility criteria)
- Life expectancy \< 10 years Men with a prostate gland larger than 60 cc, or those with a large median lobe• Hip prostheses or any other implants/hardware that introduce substantial CT artefacts making it challenging to delineate the target or organs at risk. This is to be assessed on a case-by-case basis with the available staging imaging.
- Medical conditions likely to make radiotherapy inadvisable e.g. inflammatory bowel disease, significant urinary symptoms.
- International Prostate Symptom Score (IPSS) \> 15 points
- Anticoagulation with warfarin/ bleeding tendency making fiducial placement, spacer gel insertion or brachytherapy unsafe in the opinion of the clinician
- Contraindications for Barrigel insertion such as previous documented allergic reaction to gel, previous rectal surgery or known rectal fistula.
- Participation in another concurrent treatment protocol for prostate cancer.
Key Trial Info
Start Date :
December 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2030
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT07210502
Start Date
December 1 2025
End Date
December 1 2030
Last Update
October 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Surrey NHS Foundation Trust
Guildford, Surrey, United Kingdom, GU2 7XX